Mumbai, June 12 -- The company said the US FDA had conducted an inspection at the plant and issued inspectional observations, to which it had submitted responses. Following a review of the company's responses and the Establishment Inspection Report (EIR), the regulator issued the import alert on June 10, 2026.

Dabur clarified that the order pertains only to a small section of the Silvassa manufacturing facility involved in private-label products and has no material impact on the company's financials, operations or other business activities. The affected products generate insignificant revenue for the company, it added.

The company said its domestic products are not covered by the import alert and the Silvassa plant continues to operate ...